All In Biotech

Drug Trial Radar · NCT05768139

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

880

Planned (sponsor's estimate)

Start

Apr 17, 2023

Primary completion

Jul 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

Conditions

  • Breast Cancer
  • Solid Tumors, Adult

Interventions

  • STX-478Drug

    STX-478 is a mutant-selective PI3Kα inhibitor

  • FulvestrantDrug

    Fulvestrant

  • RibociclibDrug

    Ribociclib

  • PalbociclibDrug

    Palbociclib

  • LetrozoleDrug

    Letrozole

  • AnastrozoleDrug

    Anastrozole

  • ExemestaneDrug

    Exemestane

  • TamoxifenDrug

    Tamoxifen

  • AbemaciclibDrug

    Abemaciclib

  • ImlunestrantDrug

    Imlunestrant

  • MetforminDrug

    Metformin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)Time frame: First 28 days of treatment
  2. Proportion of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: First 28 days of treatment
  3. Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1Time frame: 12 months
  4. Incidence of TEAEs/SAEs ≥ grade 2Time frame: 12 months
  5. Frequency of TEAEs according to CTCAE v5.0 criteriaTime frame: 12 months

Locations

65 sites in 9 countries. Site status is shown where the registry gives one.

  • Ellison Clinic at Saint John's

    Los Angeles, California · Recruiting

  • UCSF Medical Center at Mission Bay

    San Francisco, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Yale-New Haven Hospital

    New Haven, Connecticut · Completed

  • Florida Cancer Specialists ORLANDO/DDU

    Lake Mary, Florida · Completed

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Terminated

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • UH Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Stefanie Spielman Comprehensive Breast Center

    Columbus, Ohio · Recruiting

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon · Recruiting

  • The West Clinic, PLLC dba West Cancer Center

    Germantown, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Completed

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • USO-Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • Centre Antoine-Lacassagne

    Nice, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Not yet recruiting

  • Mater Misericordiae Hospital

    Dublin, Ireland · Recruiting

  • Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy · Recruiting

  • Spedali Civili di Brescia

    Brescia, Italy · Not yet recruiting

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.